Actively Recruiting
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Led by Shenyang Sunshine Pharmaceutical Co., LTD. · Updated on 2025-08-03
340
Participants Needed
1
Research Sites
123 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
CONDITIONS
Official Title
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females over 18 years old
- Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer, breast cancer, or gastric/gastroesophageal junction cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival of more than 3 months
- Signed informed consent form
You will not qualify if you...
- Remaining adverse events greater than grade 1 from prior anti-tumor treatment except hair loss, fatigue, and grade 2 peripheral neurotoxicity
- Pregnant or nursing women or men and women ready to have children
- Symptomatic central nervous system metastasis
- Allergy to antibody drugs or any components of the study drugs
- Inadequate organ or bone marrow function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
J
Jieer Ying, M.D
CONTACT
M
Meifang Zheng, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here